Reduced kidney levels of lysophosphatidic acids in rats after chronic administration of aristolochic acid: Its possible protective role in renal fibrosis.

Toshihiko Tsutsumi, Syougo Yamakawa, Akira Ishihara, Aimi Yamamoto, Tamotsu Tanaka, Akira Tokumura

Open access · goldAbstract read

In one paragraph

Article in Toxicology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

1.1field-weighted citation impact, top 22% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

Antimicrobial activity and acetylcholinestrase inhibition of novel synthesized pyrimidine derivatives versusToxicology reports · 2019
Article
Plasma metabolic profiling analysis of Strychnos nux-vomica Linn. and Tripterygium wilfordii Hook F-induced renal toxicity using metabolomics coupled with UPLC/Q-TOF-MS.Toxicology research · 2018
Article
Daily Intake of High-Fat Diet with Lysophosphatidic Acid-Rich Soybean Phospholipids Augments Colon Tumorigenesis in Kyoto Apc Delta Rats.Digestive diseases and sciences · 2017
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Toshihiko TsutsumiDepartment of Pharmaceutical Sciences, Kyushu University of Health and Welfare, Japan.

Syougo YamakawaDepartment of Pharmaceutical Health Chemistry, Institute of Health Biosciences, University of Tokushima Graduate School, Japan.

Akira IshiharaDepartment of Anatomic Pathology, Prefectural Nobeoka Hospital, Japan.

Aimi YamamotoDepartment of Pharmaceutical Health Chemistry, Institute of Health Biosciences, University of Tokushima Graduate School, Japan.

Tamotsu TanakaDepartment of Pharmaceutical Health Chemistry, Institute of Health Biosciences, University of Tokushima Graduate School, Japan.

Akira TokumuraDepartment of Pharmaceutical Health Chemistry, Institute of Health Biosciences, University of Tokushima Graduate School, Japan.

Tokushima University · JPKyushu University of Health and Welfare · JPMiyazaki Prefectural Hospital · JPYasuda Women's University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aristolochic acid (AA) is considered to be a causative agent for progressive interstitial renal fibrosis, leading to AA nephropathy. Lysophosphatidic acid (LPA) is a mediator in the onset of renal fibrosis. In this study, we analyzed the molecular species of LPA and its precursor lysophospholipids in kidney tissue from rats exposed to AA. Daily intraperitoneal injections of AA for 35 days to rats gave rise to fibrosis in kidney, decreased the kidney levels of LPA, lysophosphatidylserine and lysophosphatidylinositol. In rat renal cell lines (NRK52E and NRK49F), AA-induced cytotoxicity was potentiated by Ki16425, LPA

Indexed as

18S, ribosomal protein S18AA, aristolochic acidAristolochic acidAZ, azan MalloryChronic kidney diseaseFibrosisGAPDH, glyceraldehyde 3-phosphate dehydrogenaseHE, hematoxylin/eosinLC–MS/MS, liquid chromatography–tandem mass spectrometryLPA, lysophosphatidic acidLPC, lysophosphatidylcholineLPE, lysophosphatidylethanolamineLPG, lysophosphatidylglycerolLPI, lysophosphatidylinositolLPL, lysophospholipidLPS, lysophosphatidylserineLysophosphatidic acidLysophospholipidlysoPLD, lysophospholipase DNephrotoxicityPLA1, phospholipase A1PLA2, phospholipase A2α-SMA, α-smooth muscle actin

Identifiers

PMID28962344

DOI10.1016/j.toxrep.2015.02.012

PMCPMC5598376

OpenAlexW2033026620

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.